Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.60 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.56 |
| ▸ | GPR142 | Q7Z601 | 8/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2724788 | 0.91 | PIK3CA (0.55) | PIK3CAUSP30GPR142GPR119CREBBP | |
| SCHEMBL3277720 | 0.91 | USP30 (0.58) | PIK3CAUSP30GPR142GPR119MAPK1 | |
| SCHEMBL2723942 | 0.88 | PIK3CA (0.52) | PIK3CAUSP30GPR142CREBBPRIPK1 | |
| SCHEMBL855899 | 0.87 | PIK3CA (0.51) | PIK3CAUSP30GPR142CREBBPRIPK1 | |
| SCHEMBL3276575 | 0.87 | CREBBP (0.54) | PIK3CAGPR142MAPK1CREBBPRIPK1 | |
| SCHEMBL856145 | 0.87 | NR1H2 (0.48) | PIK3CAUSP30GPR142GPR119CREBBP | |
| SCHEMBL3808847 | 0.86 | GPR142 (0.51) | PIK3CAGPR142CREBBPRIPK1 | |
| SCHEMBL3749703 | 0.84 | PIK3CA (0.48) | PIK3CAUSP30GPR142GPR119MAPK1 | |
| SCHEMBL7858946 | 0.84 | PIK3CA (0.44) | PIK3CAUSP30GPR142GPR119CREBBP | |
| SCHEMBL11985662 | 0.84 | MAPK1 (0.57) | USP30GPR119MAPK1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2123644-B1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8247403-B2 | Benzoxazepine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-04-08 | — | — | US | disclosed |
| EP-2123644-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | HTR2C, HTR5A, HTR2B | PIK3CA 2630/4885USP30 4155/4885GPR142 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.